Pogosov
Market closed · Pre-market opens in
EN|RU
--:--:--NY

← ANALYST RATINGS · TIPRANKS

Avalyn Pharma Inc (AVLN): analyst forecast and price target

$23.66 −3.98% close 16.10.26 · market cap $1.1B · General · Biotechnology IWM 0.02%
Price targets and ratings of
All analysts Top analysts

Analyst consensus

Strong Buy

3 Buy0 Hold0 Sell

Ratings of 3 analysts in the last 3 months

12-month forecast

$56.33+138.1% upside

Based on 3 price targets given in the last 3 months, the average target is $56.33, the highest $60.00, the lowest $52.00. The average is +138.1% from the last price of $23.66.

$40.00$60.00JulOctJan 27AprJulOctHigh$60.00Average$56.33Low$52.00
Highest target $60.00 Average target $56.33 Lowest target $52.00

Analyst ratings 4

Analysts TipRanks AI models 0 All
Any rating BuyHoldSell
All actions Only changes
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% Raymond James $60.00 Buy +153.6% Initiated 02.10.26on TipRanks 08:00 +1.8%next day −4.6% · 5 days −9.6% ↗
Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% Jefferies $52.00 Buy +119.8% Reiterated 13.08.26on TipRanks 10:45 −2.8%next day +7.5% · 5 days +3.5% ↗
Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% Morgan Stanley $53.00 → $57.00+7.5% Buy +140.9% Assigned 13.08.26on TipRanks 07:55 −2.8%next day +7.5% · 5 days +3.5% ↗
Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% Evercore ISI $51.00 Buy +115.6% Initiated 26.05.26on TipRanks Jun 3 21:15 −8.1%next day +0.5% · 5 days −4.9% ↗

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Avalyn Pharma Inc

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
1 year Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
2 years Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%

Most profitable

3 months Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
1 year Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
2 years Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.50 at a price of $28.49 (+91.3%); now: $56.33 at $23.66 (+138.1%).

$40.00$60.00Sep 15Oct 1Oct 15Top analysts$60.00Average target$56.33Price$23.66

PriceAverage targetTop analysts’ target

Recommendation trend

01234Oct 25NovDecJan 26FebMarApr3May4Jun4Jul21Aug11Sep21Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy344212
Buy000111
Hold000000
Sell000000

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About Avalyn Pharma Inc
  • CEO: Lyn Baranowski
  • Employees: 55
  • 105 W First St. Boston, Boston, MA, 02127, US
  • www.avalynpharma.com

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Data from the stock’s TipRanks forecast page, read 17 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗